Sulforaphane Inhibits Adhesion and Migration of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro

被引:2
|
作者
Xie, Hui [1 ,2 ]
Rutz, Jochen [1 ]
Maxeiner, Sebastian [1 ]
Grein, Timothy [2 ]
Thomas, Anita [1 ]
Juengel, Eva [1 ]
Chun, Felix K. -H. [2 ]
Cinatl, Jindrich [3 ]
Haferkamp, Axel [1 ]
Tsaur, Igor [1 ]
Blaheta, Roman A. [1 ,2 ]
机构
[1] Univ Med Ctr Mainz, Dept Urol & Pediat Urol, D-55131 Mainz, Germany
[2] Goethe Univ, Dept Urol, D-60590 Frankfurt, Germany
[3] Goethe Univ, Inst Med Virol, D-60596 Frankfurt, Germany
关键词
sulforaphane; bladder cancer; drug-resistance; chemotaxis; integrins; cadherins; BETA-CATENIN; EXPRESSION; SENSITIVITY;
D O I
10.3390/nu16050623
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Only 20% of patients with muscle-invasive bladder carcinoma respond to cisplatin-based chemotherapy. Since the natural phytochemical sulforaphane (SFN) exhibits antitumor properties, its influence on the adhesive and migratory properties of cisplatin- and gemcitabine-sensitive and cisplatin- and gemcitabine-resistant RT4, RT112, T24, and TCCSUP bladder cancer cells was evaluated. Mechanisms behind the SFN influence were explored by assessing levels of the integrin adhesion receptors beta 1 (total and activated) and beta 4 and their functional relevance. To evaluate cell differentiation processes, E- and N-cadherin, vimentin and cytokeratin (CK) 8/18 expression were examined. SFN down-regulated bladder cancer cell adhesion with cell line and resistance-specific differences. Different responses to SFN were reflected in integrin expression that depended on the cell line and presence of resistance. Chemotactic movement of RT112, T24, and TCCSUP (RT4 did not migrate) was markedly blocked by SFN in both chemo-sensitive and chemo-resistant cells. Integrin-blocking studies indicated beta 1 and beta 4 as chemotaxis regulators. N-cadherin was diminished by SFN, particularly in sensitive and resistant T24 and RT112 cells, whereas E-cadherin was increased in RT112 cells (not detectable in RT4 and TCCSup cells). Alterations in vimentin and CK8/18 were also apparent, though not the same in all cell lines. SFN exposure resulted in translocation of E-cadherin (RT112), N-cadherin (RT112, T24), and vimentin (T24). SFN down-regulated adhesion and migration in chemo-sensitive and chemo-resistant bladder cancer cells by acting on integrin beta 1 and beta 4 expression and inducing the mesenchymal-epithelial translocation of cadherins and vimentin. SFN does, therefore, possess potential to improve bladder cancer therapy.
引用
收藏
页数:14
相关论文
共 50 条
  • [11] Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
    Minami, Kentaro
    Shinsato, Yoshinari
    Yamamoto, Masatatsu
    Takahashi, Homare
    Zhang, Shaoxuan
    Nishizawa, Yukihiko
    Tabata, Sho
    Ikeda, Ryuji
    Kawahara, Kohich
    Tsujikawa, Kazutake
    Chijiiwa, Kazuo
    Yamada, Katsushi
    Akiyama, Shin-ichi
    Perez-Torras, Sandra
    Pastor-Anglada, Marcal
    Furukawa, Tatsuhiko
    Yasuo, Takeda
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 127 (03) : 319 - 325
  • [12] Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells
    Zhang, Su
    Chang, Yong-Yan
    Gong, Yu-Wen
    Gao, Yan-Jun
    Guo, Qi
    Wang, Yu-Han
    Zhao, You-Li
    Wang, Zhi-Ping
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (04) : 6347 - 6360
  • [13] Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization
    Yan, Tao
    Li, Hai-Ying
    Wu, Jian-Song
    Niu, Qiang
    Duan, Wei-Hong
    Han, Qing-Zeng
    Ji, Wang-Ming
    Zhang, Tao
    Lv, Wei
    ONCOLOGY LETTERS, 2017, 14 (05) : 5400 - 5408
  • [14] IFN-γ induces apoptosis in gemcitabine-resistant pancreatic cancer cells
    Kong, Xiangxin
    Cheng, Denglong
    Xu, Xu
    Zhang, Yuan
    Li, Xin
    Pan, Wanlong
    MOLECULAR MEDICINE REPORTS, 2024, 29 (05)
  • [15] Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer Cells by Altering Integrins
    Vakhrusheva, Olesya
    Zhao, Fuguang
    Markowitsch, Sascha Dennis
    Slade, Kimberly Sue
    Brandt, Maximilian Peter
    Tsaur, Igor
    Cinatl Jr, Jindrich
    Michaelis, Martin
    Efferth, Thomas
    Blaheta, Roman Alexander
    Haferkamp, Axel
    Juengel, Eva
    CELLS, 2025, 14 (08)
  • [16] Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer
    Seo, Ho Kyung
    Ahn, Kyung-Ohk
    Jung, Nae-Rae
    Shin, Ji-Sun
    Park, Weon Seo
    Lee, Kang Hyun
    Lee, Sang-Jin
    Jeong, Kyung-Chae
    ONCOTARGET, 2014, 5 (02) : 326 - 337
  • [17] Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition
    Jin, Hangbin
    Zhao, Yanyan
    Zhang, Shirong
    Yang, Jianfeng
    Zhang, Xiaofeng
    Ma, Shenglin
    MOLECULAR MEDICINE REPORTS, 2018, 17 (05) : 7274 - 7280
  • [18] Celastrol Inhibits the Proliferation and Decreases Drug Resistance of Cisplatin- Resistant Gastric Cancer SGC7901/DDP Cells
    Zhan, Dongmei
    Ni, Tengyang
    Wang, Haibo
    Lv, Mengying
    Sunagawa, Masataka
    Liu, Yanqing
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (02) : 270 - 279
  • [19] Heat-shock Protein 27 Is Phosphorylated in Gemcitabine-resistant Pancreatic Cancer Cells
    Taba, Kumiko
    Kuramitsu, Yasuhiro
    Ryozawa, Shomei
    Yoshida, Kanako
    Tanaka, Toshiyuki
    Maehara, Shin-Ichiro
    Maehara, Yoshihiro
    Sakaida, Isao
    Nakamura, Kazuyuki
    ANTICANCER RESEARCH, 2010, 30 (07) : 2539 - 2543
  • [20] Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin
    Muramaki, Mototsugu
    So, Alan
    Hayashi, Norihiro
    Sowery, Richard
    Miyake, Hideaki
    Fujisawa, Masato
    Gleave, Martin E.
    BJU INTERNATIONAL, 2009, 103 (03) : 384 - 390